Reports
Reports
The global cancer/tumour profiling market attained a value of USD around 10.44 billion in 2023. The cancer/tumour profiling market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 10.2% to reach USD 25.07 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising rate of cancer globally and the growing use of biomarkers in the production of tumours are the main drivers for the growth of the cancer/tumour profiling market.
Cancer is a life-threatening illness that is characterised by uncontrolled cell growth. This is mainly due to environmental reasons which alter the gene encoding that regulates cells. The resulting cell mutation results in abnormal cell growth, killing the surrounding normal tissue and then spreading it to very important organs. Cancer/tumour profiling is done to gain insight into a patient's cancer profile and genomic adjustments that enable physicians to guide a patient to the most appropriate treatment. Therefore, profiling also allows doctors to avoid interventions that are questionable and, thus, reduce mistakes and trial procedures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The types of cancer can be divided into:
The types of biosensors can be segmented into:
The cancer/tumour profiling market can be broadly categorised based on technology into:
It finds its uses in the research and clinical applications.
Research applications can be further divided into:
Clinical applications are further categorised into:
The EMR report looks into the regional markets of cancer/tumour profiling like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A significant growth in the global market for cancer/tumour profiling is expected in the coming years, mainly owing to the increased funding of activities to improve the overall course of the diagnosis and treatment of the disease and the recent comprehensive technological advancements in the area of tumour profiling. The market is also being driven by the growing use of medical diagnostics and the resulting increase in the demand for personalized medicinal products.
The constantly increasing socio-economic burden of cancer and the demand from the health industry to establish effective methods of treating and controlling it also drives the market for the profiling of cancer/tumours. Nonetheless, the additional expenditure needed by profiling procedures may in some way impede its adoption, limiting the scope of these processes to high-income regions. Nonetheless, through government intervention and support from the public and private institutions for cancer diagnosis and treatment are expected to allow the market to achieve promising avenues for development.
The report presents a detailed analysis of the following key players in the global cancer/tumour profiling market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the cancer/tumour profiling market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Biomarker Type, Technology, Application, Region |
Breakup by Cancer Type | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others |
Breakup by Biomarker Type | Genetic Biomarkers, Protein Biomarkers, Others |
Breakup by Technology | Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Microarrays, Mass Spectrometry, Others |
Breakup by Application | Research Applications, Clinical Applications |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Illumina, Inc. (NASDAQ: ILMN), Qiagen N.V. (NYSE: QGEN), Neogenomic Laboratories, Inc. (NASDAQ: NEO), Sysmex Corporation (TYO: 6869), HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM), Helomics Corporation, Caris Life Sciences, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Cancer/Tumour Profiling Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer/Tumour Profiling Historical Market (2018-2023)
8.3 Global Cancer/Tumour Profiling Market Forecast (2024-2032)
8.4 Global Cancer/Tumour Profiling Market by Cancer Type
8.4.1 Breast Cancer
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Lung Cancer
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Colorectal Cancer
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Prostate Cancer
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 Melanoma
8.4.5.1 Historical Trend (2018-2023)
8.4.5.2 Forecast Trend (2024-2032)
8.4.6 Others
8.5 Global Cancer/Tumour Profiling Market by Biomarker Type
8.5.1 Genetic Biomarkers
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Protein Biomarkers
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Others
8.6 Global Cancer/Tumour Profiling Market by Technology
8.6.1 Immunoassays
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Next-Generation Sequencing
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Polymerase Chain Reaction
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 In Situ Hybridization
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Microarrays
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
8.6.6 Mass Spectrometry
8.6.6.1 Historical Trend (2018-2023)
8.6.6.2 Forecast Trend (2024-2032)
8.6.7 Others
8.7 Global Cancer/Tumour Profiling Market by Application
8.7.1 Research Applications
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.1.3 Breakup by Type
8.7.1.3.1 Biomarker Discovery
8.7.1.3.2 Personalised Medicine
8.7.2 Clinical Applications
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.2.3 Breakup by Type
8.7.2.3.1 Diagnostics
8.7.2.3.2 Prognostics
8.7.2.3.3 Monitoring and Treatment
8.7.2.3.4 Screening
8.8 Global Cancer/Tumour Profiling Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2018-2023)
8.8.1.2 Forecast Trend (2024-2032)
8.8.2 Europe
8.8.2.1 Historical Trend (2018-2023)
8.8.2.2 Forecast Trend (2024-2032)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2018-2023)
8.8.3.2 Forecast Trend (2024-2032)
8.8.4 Latin America
8.8.4.1 Historical Trend (2018-2023)
8.8.4.2 Forecast Trend (2024-2032)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2018-2023)
8.8.5.2 Forecast Trend (2024-2032)
9 North America Cancer/Tumour Profiling Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Cancer/Tumour Profiling Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Cancer/Tumour Profiling Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.2 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Cancer/Tumour Profiling Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Cancer/Tumour Profiling Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Illumina, Inc.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Qiagen N.V.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 NeoGenomics Laboratories, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Sysmex Corporation
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 HTG Molecular Diagnostics, Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Helomics Corporation
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Caris Life Sciences
16.2.7.1 Company Overview
16.2.7.2 Product Portfolio
16.2.7.3 Demographic Reach and Achievements
16.2.7.4 Certifications
16.2.8 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Cancer/Tumour Profiling Market: Key Industry Highlights, 2018 and 2032
2. Global Cancer/Tumour Profiling Historical Market: Breakup by Cancer Type (USD Billion), 2018-2023
3. Global Cancer/Tumour Profiling Market Forecast: Breakup by Cancer Type (USD Billion), 2024-2032
4. Global Cancer/Tumour Profiling Historical Market: Breakup by Biomarker Type (USD Billion), 2018-2023
5. Global Cancer/Tumour Profiling Market Forecast: Breakup by Biomarker Type (USD Billion), 2024-2032
6. Global Cancer/Tumour Profiling Historical Market: Breakup by Technology (USD Billion), 2018-2023
7. Global Cancer/Tumour Profiling Market Forecast: Breakup by Technology (USD Billion), 2024-2032
8. Global Cancer/Tumour Profiling Historical Market: Breakup by Application (USD Billion), 2018-2023
9. Global Cancer/Tumour Profiling Market Forecast: Breakup by Application (USD Billion), 2024-2032
10. Global Cancer/Tumour Profiling Historical Market: Breakup by Region (USD Billion), 2018-2023
11. Global Cancer/Tumour Profiling Market Forecast: Breakup by Region (USD Billion), 2024-2032
12. North America Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2018-2023
13. North America Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Europe Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Europe Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Asia Pacific Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Asia Pacific Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Latin America Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Latin America Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Middle East and Africa Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2018-2023
21. Middle East and Africa Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2024-2032
22. Global Cancer/Tumour Profiling Market Structure
In 2023, the global cancer/tumour profiling market attained a value of nearly USD 10.44 billion.
The market is projected to grow at a CAGR of 10.2% between 2024 and 2032.
The industry is being driven by the rising global incidences of cancer and the expanding usage of biomarkers in identifying the formation of tumours.
The key trends augmenting the market expansion in the forecast period are the increasing funding for activities aimed at improving the overall course of disease diagnosis and treatment, technological advancements in tumour profiling, and the increasing demand for individualised pharmaceutical products.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The various cancer types in the industry are breast cancer, lung cancer, colorectal cancer, prostate cancer, and melanoma, among others.
The major biomarker types of cancer/tumour profiling are genetic biomarkers and protein biomarkers, among others.
The significant technologies of cancer/tumour profiling in the market are immunoassays, next-generation sequencing, polymerase chain reaction, in situ hybridisation, microarrays, and mass spectrometry, among others.
The several applications of cancer/tumour profiling in the market are research applications and clinical applications.
The major players in the industry are Illumina, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Sysmex Corporation, HTG Molecular Diagnostics, Inc., Helomics Corporation, and Caris Life Sciences, among others.
The global cancer/tumour profiling market attained a value of about USD 10.44 billion in 2023, driven by the rising global incidences of cancer. Aided by technological advancements in tumour profiling, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 10.2%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its cancer types, the cancer/tumour profiling industry can be segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and melanoma, among others. By biomarker types, the industry can be divided into genetic biomarkers and protein biomarkers, among others. On the basis of technology, the market is classified into immunoassays, next-generation sequencing, polymerase chain reaction, in situ hybridisation, microarrays, and mass spectrometry, among others. Based on application, the industry is bifurcated into research activities and clinical applications. The major regional markets for cancer/tumour profiling are North America, Latin America, Europe, the Middle East and Africa, the Asia Pacific. The key players in the above market include Illumina, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Sysmex Corporation, HTG Molecular Diagnostics, Inc., Helomics Corporation, and Caris Life Sciences, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.